Fuller & Thaler Asset Management
LGND icon

Fuller & Thaler Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Fuller & Thaler Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-71,558
Closed -$6.06M – 468
2018
Q4 		$6.06M Buy
+71,558
New +$7.63M 0.09% 168

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Fuller & Thaler Asset Management's LGND Position: Q1 2019 in Review

Fuller & Thaler Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 71,558 shares — an estimated $6.06M sold.

Fuller & Thaler Asset Management first reported a position in LGND in Q4 2018 and held it in 1 quarter. The position peaked at $6.06M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Fuller & Thaler Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 71,558 Ligand Pharmaceuticals shares in Q1 2019, an estimated $6.06M.
  • Fuller & Thaler Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Fuller & Thaler Asset Management's Ligand Pharmaceuticals position peaked at $6.06M in Q4 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2019, filed 14 May 2019.